

Richard A Hansen, Rph, Fapha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4587538/publications.pdf>

Version: 2024-02-01

112
papers

3,876
citations

147801

31
h-index

133252

59
g-index

112
all docs

112
docs citations

112
times ranked

5697
citing authors

#	ARTICLE	IF	CITATIONS
1	The Burden of Gastrointestinal and Liver Diseases, 2006. American Journal of Gastroenterology, 2006, 101, 2128-2138.	0.4	577
2	Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2014, 75, 477-489.	2.2	256
3	Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence. Annals of Pharmacotherapy, 2009, 43, 413-422.	1.9	244
4	A simple and valid tool distinguished efficacy from effectiveness studies. Journal of Clinical Epidemiology, 2006, 59, 1040-1048.	5.0	176
5	Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis. Drug Safety, 2014, 37, 19-31.	3.2	119
6	Comparative Risk for Harms of Second-Generation Antidepressants. Drug Safety, 2008, 31, 851-865.	3.2	118
7	Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes. Annals of Family Medicine, 2006, 4, 253-262.	1.9	116
8	Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety, 2017, 16, 761-767.	2.4	112
9	Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events. Clinical Gastroenterology and Hepatology, 2007, 5, 729-735.e1.	4.4	97
10	Impact of eHealth on medication adherence among patients with asthma: A systematic review and meta-analysis. Respiratory Medicine, 2019, 149, 59-68.	2.9	83
11	Functional Outcomes of Drug Treatment in Alzheimer's Disease. Drugs and Aging, 2007, 24, 155-167.	2.7	72
12	Prevalence of depressive symptoms and predictors of treatment among U.S. adults from 2005 to 2010. General Hospital Psychiatry, 2014, 36, 330-336.	2.4	72
13	Treating Depression After Initial Treatment Failure. Journal of Clinical Psychopharmacology, 2012, 32, 114-119.	1.4	69
14	Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clinical Rheumatology, 2007, 27, 67-76.	2.2	68
15	Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants. Psychiatric Services, 2008, 59, 1121-1130.	2.0	67
16	Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovascular Disorders, 2012, 12, 93.	1.7	65
17	Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study*. Inflammatory Bowel Diseases, 2012, 18, 1048-1056.	1.9	61
18	Preventing medication errors in long-term care: results and evaluation of a large scale web-based error reporting system. Quality and Safety in Health Care, 2007, 16, 297-302.	2.5	60

#	ARTICLE	IF	CITATIONS
19	A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the united states from 2003 to 2005. <i>Clinical Therapeutics</i> , 2010, 32, 1308-1319.	2.5	58
20	Prescriber Continuity and Medication Adherence for Complex Patients. <i>Annals of Pharmacotherapy</i> , 2015, 49, 293-302.	1.9	51
21	COMPARATIVE EFFECTIVENESS OF SECOND-GENERATION ANTIDEPRESSANTS FOR ACCOMPANYING ANXIETY, INSOMNIA, AND PAIN IN DEPRESSED PATIENTS: A SYSTEMATIC REVIEW. <i>Depression and Anxiety</i> , 2012, 29, 495-505.	4.1	50
22	Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. <i>International Clinical Psychopharmacology</i> , 2005, 20, 59-69.	1.7	48
23	Factors associated with potentially inappropriate drug utilization in a sample of rural community-dwelling older adults. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005, 3, 168-179.	3.0	43
24	Types of medication errors in north carolina nursing homes: A target for quality improvement. <i>American Journal of Geriatric Pharmacotherapy</i> , 2006, 4, 52-61.	3.0	43
25	Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose. <i>Medical Decision Making</i> , 2009, 29, 91-103.	2.4	41
26	Prescription refill records as a screening tool to identify antidepressant non-adherence. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 33-37.	1.9	38
27	Repeat medication errors in nursing homes: Contributing factors and their association with patient harm. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 258-270.	3.0	38
28	Osteoporosis beliefs and antiresorptive medication use. <i>Maturitas</i> , 2005, 50, 196-208.	2.4	36
29	The Intersection of Patient Complexity, Prescriber Continuity and Acute Care Utilization. <i>Journal of General Internal Medicine</i> , 2014, 29, 594-601.	2.6	36
30	The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder. <i>Drug Safety</i> , 2009, 32, 1159-1173.	3.2	32
31	Medication Errors During Patient Transitions into Nursing Homes: Characteristics and Association With Patient Harm. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 413-422.	3.0	32
32	Direct-to-Consumer and Physician Promotion of Tegaserod Correlated With Physician Visits, Diagnoses, and Prescriptions. <i>Gastroenterology</i> , 2009, 137, 518-524.e2.	1.3	31
33	Adherence to Antipsychotics and Cardiometabolic Medication: Association With Health Care Utilization and Costs. <i>Psychiatric Services</i> , 2012, 63, 920-928.	2.0	31
34	Treating the Physical Symptoms of Depression With Second-Generation Antidepressants: A Systematic Review and Metaanalysis. <i>Psychosomatics</i> , 2008, 49, 191-198.	2.5	29
35	Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 125-130.	0.9	28
36	Tumor Necrosis Factor- α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 2129-2136.	2.0	28

#	ARTICLE	IF	CITATIONS
37	Factors influencing the shift of patients from one proton pump inhibitor to another: The effect of direct-to-consumer advertising. <i>Clinical Therapeutics</i> , 2005, 27, 1478-1487.	2.5	26
38	Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2008, 23, 170-179.	1.7	25
39	Effect of Ropinirole on Sleep Outcomes in Patients with Restless Legs Syndrome: Meta-Analysis of Pooled Individual Patient Data from Randomized Controlled Trials. <i>Pharmacotherapy</i> , 2009, 29, 255-262.	2.6	25
40	Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 760-768.	1.5	25
41	Exploratory Evaluation of Medication Classes Most Commonly Involved in Nursing Home Errors. <i>Journal of the American Medical Directors Association</i> , 2013, 14, 403-408.	2.5	25
42	Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Annals of Pharmacotherapy</i> , 2016, 50, 253-261.	1.9	25
43	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. <i>Arthritis Care and Research</i> , 2016, 68, 1078-1088.	3.4	24
44	Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 93-102.	0.9	23
45	How Should Primary Care Doctors Select Which Antidepressants to Administer?. <i>Current Psychiatry Reports</i> , 2012, 14, 360-369.	4.5	22
46	Guideline-concordant antidepressant use among patients with major depressive disorder. <i>General Hospital Psychiatry</i> , 2010, 32, 360-367.	2.4	19
47	Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. <i>Pharmacotherapy</i> , 2017, 37, 429-437.	2.6	19
48	Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Epilepsy Research</i> , 2017, 135, 71-78.	1.6	19
49	Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis. <i>CNS Drugs</i> , 2014, 28, 699-712.	5.9	18
50	Predialysis chronic kidney disease: Evaluation of quality of life in clinic patients receiving comprehensive anemia care. <i>Research in Social and Administrative Pharmacy</i> , 2009, 5, 143-153.	3.0	17
51	How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies?. <i>Drug Safety</i> , 2013, 36, 27-32.	3.2	17
52	Risk of Adverse Gastrointestinal Events from Inhaled Corticosteroids. <i>Pharmacotherapy</i> , 2008, 28, 1325-1334.	2.6	16
53	Treatment Use and Costs Among Privately Insured Youths With Diagnoses of Bipolar Disorder. <i>Psychiatric Services</i> , 2012, 63, 1019-1025.	2.0	16
54	Distinguishing characteristics of patients who seek more information or request a prescription in response to direct-to-consumer advertisements. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 231-250.	3.0	15

#	ARTICLE	IF	CITATIONS
55	Risk of hyperkalemia associated with selective COX ² inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1194-1198.	1.9	15
56	Prevalence of Bipolar Disorder Diagnoses and Psychotropic Drug Therapy Among Privately Insured Children and Adolescents. <i>Pharmacotherapy</i> , 2012, 32, 1085-1094.	2.6	15
57	Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1491-1505.	1.9	15
58	Methodological challenges surrounding direct-to-consumer advertising research ¹ The measurement conundrum. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 331-347.	3.0	13
59	Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 138-144.	1.9	13
60	Antipsychotic Adherence and Its Correlation to Health Outcomes for Chronic Comorbid Conditions. primary care companion for CNS disorders, <i>The</i> , 2012, 14, .	0.6	13
61	The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use [†] . <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 139-157.	3.0	12
62	Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. <i>Depression and Anxiety</i> , 2011, 28, 989-998.	4.1	12
63	Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs. <i>Drug Safety</i> , 2018, 41, 363-376.	3.2	12
64	Patterns in nursing home medication errors: disproportionality analysis as a novel method to identify quality improvement opportunities. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1087-1094.	1.9	11
65	Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. <i>General Hospital Psychiatry</i> , 2012, 34, 192-200.	2.4	11
66	Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs. <i>Clinical Drug Investigation</i> , 2016, 36, 281-292.	2.2	11
67	Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Clinical Drug Investigation</i> , 2017, 37, 1143-1152.	2.2	11
68	Analgesic Medication Errors in North Carolina Nursing Homes. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2013, 27, 125-131.	0.8	10
69	Developing an expert panel process to refine health outcome definitions in observational data. <i>Journal of Biomedical Informatics</i> , 2013, 46, 795-804.	4.3	10
70	Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: Results of a retrospective database analysis. <i>Clinical Therapeutics</i> , 2006, 28, 979-989.	2.5	9
71	Effect of Second-Generation Antidepressants on Mania- and Depression-Related Visits in Adults with Bipolar Disorder: A Retrospective Study. <i>Value in Health</i> , 2007, 10, 128-136.	0.3	9
72	Inadequate reporting of trials compromises the applicability of systematic reviews. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 323-330.	0.5	9

#	ARTICLE	IF	CITATIONS
73	Methodology of a pilot study to improve the quality of medication use in older adults: Enhancing quality in psychiatry using pharmacists (EQUIPP). American Journal of Geriatric Pharmacotherapy, 2009, 7, 362-372.	3.0	9
74	Utilization Patterns of Antihypertensive Drugs Among the Chronic Kidney Disease Population in the United States: A Cross-sectional Analysis of the National Health and Nutrition Examination Survey. Clinical Therapeutics, 2015, 37, 188-196.	2.5	9
75	Ranking antidepressants. Lancet, The, 2009, 373, 1761.	13.7	8
76	Part D Plan Enrollment by Uninsured Medicare Beneficiaries. Medical Care, 2010, 48, 183-186.	2.4	8
77	Geographic Information System mapping as a tool to assess nonresponse bias in survey research. Research in Social and Administrative Pharmacy, 2007, 3, 249-264.	3.0	7
78	Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record. BMC Endocrine Disorders, 2013, 13, 24.	2.2	7
79	Expert panel assessment of acute liver injury identification in observational data. Research in Social and Administrative Pharmacy, 2014, 10, 156-167.	3.0	7
80	Treatment patterns among breast cancer patients in the United States using two national surveys on visits to physicians' offices and hospital outpatient departments. Research in Social and Administrative Pharmacy, 2015, 11, 708-720.	3.0	7
81	How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer?. Research in Social and Administrative Pharmacy, 2020, 16, 1087-1094.	3.0	7
82	Performance of Medometer visual tool for measuring medication adherence and comparison with other measures. Journal of the American Pharmacists Association: JAPhA, 2013, 53, 198-205.	1.5	6
83	Continuity of medication management among adults with schizophrenia and comorbid cardiometabolic conditions. Journal of Pharmaceutical Health Services Research, 2018, 9, 13-20.	0.6	6
84	Disparities in the appropriateness of medication use: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population-based cohort study. Research in Social and Administrative Pharmacy, 2020, 16, 1702-1710.	3.0	6
85	The impact of cognitive impairment on survival and medication adherence among older women with breast cancer. Breast Cancer, 2021, 28, 277-288.	2.9	6
86	The study of direct-to-consumer advertising for prescription drugs. Research in Social and Administrative Pharmacy, 2005, 1, 348-368.	3.0	5
87	Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. Annals of Epidemiology, 2013, 23, 204-209.	1.9	5
88	Exploration of heterogeneity in distributed research network drug safety analyses. Research Synthesis Methods, 2014, 5, 352-370.	8.7	5
89	Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug & Effectiveness Review Project. Biologics: Targets and Therapy, 2009, , 485.	3.2	4
90	Are some antidepressants better than others?. Nature Reviews Neurology, 2009, 5, 239-240.	10.1	4

#	ARTICLE	IF	CITATIONS
91	Enhancing Quality in Psychiatry with Psychiatrists (EQUIPP)â€”Results from a Pilot Study. American Journal of Geriatric Psychiatry, 2014, 22, 884-888.	1.2	4
92	Factors associated with psychotropic prescriptions, psychiatric hospitalization, and spending among Medicare beneficiaries under 65. Disability and Health Journal, 2015, 8, 424-433.	2.8	4
93	Achieving Adherence After Firstâ€”Line Antihypertensive Treatment: Should Fixedâ€”Dose Combinations Receive Priority?. Journal of Clinical Hypertension, 2016, 18, 934-941.	2.0	4
94	Continuity of medication management in Medicaid patients with chronic comorbid conditions: An examination by mental health status. General Hospital Psychiatry, 2017, 45, 25-31.	2.4	4
95	Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study. Clinical Therapeutics, 2019, 41, 1128-1138.e8.	2.5	4
96	Patterns of psychiatric emergency department utilization among community-dwelling Medicare beneficiaries under 65.. Psychological Services, 2017, 14, 387-396.	1.5	4
97	Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs. Expert Opinion on Drug Safety, 2018, 17, 753-756.	2.4	3
98	Healthcare provider opinions about a generic drug educational newsletter. Research in Social and Administrative Pharmacy, 2020, 16, 1228-1236.	3.0	3
99	Disseminating Comparative Effectiveness Research Through Community-based Experiential Learning. American Journal of Pharmaceutical Education, 2017, 81, 9.	2.1	3
100	Authors' reply to comment on: a simple and valid tool distinguished efficacy from effectiveness studies. Journal of Clinical Epidemiology, 2007, 60, 755.	5.0	2
101	Online Medication Error Graphic Reports. Journal of Patient Safety, 2011, 7, 92-98.	1.7	2
102	Patterns of treatment modifications among newly treated hypertensive patients. Journal of Hypertension, 2016, 34, 548-557.	0.5	2
103	The association of continuity of care and risk of mortality in breast cancer patients with cardiometabolic comorbidities. Journal of Psychosocial Oncology, 2021, , 1-15.	1.2	2
104	Understanding authorized genericsâ€”A review of the published clinical data. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1489-1497.	1.5	2
105	Paediatric <i>Helicobacter pylori</i> Practice in the United Kingdom. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 339-339.	1.8	1
106	Authors' Reply to Courtney Suggs and Colleaguesâ€™ Comment on: â€œMixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugsâ€• Drug Safety, 2018, 41, 1423-1424.	3.2	1
107	An Examination of Prescribing Responsibilities between Psychiatrists and Primary Care Providers. Psychiatric Quarterly, 2021, 92, 587-600.	2.1	1
108	Perceived appropriateness of medication adherence incentives. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 772-778.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Disparities in Cognitive Impairment With Anticholinergic Drug Use. <i>Neurology: Clinical Practice</i> , 2021, 11, e277-e286.	1.6	1
110	Systematic Review of Biliary Atresia Services. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, e19-20.	1.8	0
111	The association between antidepressants use and development of cognitive impairment among older women diagnosed with breast cancer. <i>European Geriatric Medicine</i> , 2020, 11, 1017-1026.	2.8	0
112	Primary Care Physicians [™] , Psychiatrists [™] , and Oncologists [™] Coordination While Prescribing Medications for Patients With Multiple Chronic Conditions. <i>Journal of Patient Safety</i> , 2021, Publish Ahead of Print, e424-e430.	1.7	0